Literature DB >> 27859017

Patterns of recurrence after oesophagectomy and postoperative chemoradiotherapy versus surgery alone for oesophageal squamous cell carcinoma.

P-K Hsu1,2, H-S Chen3, C-S Huang1,2, C-C Liu4, C-C Hsieh1,2, H-S Hsu1,2, Y-C Wu1,2, S-C Wu3.   

Abstract

BACKGROUND: Patterns of recurrence after surgery with postoperative chemoradiotherapy (S-CCRT) or surgery alone in patients with oesophageal squamous cell carcinoma (SCC) may differ. This might influence the nature and timing of subsequent management strategies.
METHODS: Patients with SCC who had undergone R0 resection were included. Propensity score matching was used to select matched groups. Survival and recurrence were compared by Kaplan-Meier analysis. Univariable and multivariable Cox regression analyses were used to identify prognostic factors for overall and disease-free survival.
RESULTS: A total of 1390 patients were included, of whom 1000 had surgery alone and 390 underwent S-CCRT. Propensity score matching yielded 213 well balanced pairs. The 3-year overall survival rate and median survival time in the S-CCRT group were 0·50 and 36·5 (95 per cent c.i. 25·1 to 52·6) months respectively, compared with 0·38 and 22·8 (18·2 to 29·0) months in the surgery-alone group (P = 0·006). The 3-year disease-free survival rate and median disease-free survival time in the S-CCRT group were 0·46 and 30·6 (22·2 to 39·3) months respectively, compared with 0·36 and 17·6 (11·3 to 23·9) months in the surgery-alone group (P = 0·006). The 2-year freedom from locoregional recurrence rate was 0·87 and 0·77 in the S-CCRT and surgery-alone groups respectively (P = 0·003). In multivariable analysis, independent prognostic factors for disease-free survival included age over 56 years, pT3-4 category, pN category, poor differentiation, tumour length exceeding 4·0 cm, and receiving postoperative chemoradiotherapy (hazard ratio 0·62, 95 per cent c.i. 0·47 to 0·81; P < 0·001).
CONCLUSION: Oesophagectomy with postoperative chemoradiotherapy was associated with longer survival and lower recurrence rates, especially at a locoregional level, compared with surgery alone.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27859017     DOI: 10.1002/bjs.10334

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

1.  Expression of miRNA in 5-FU resistant esophageal cancer.

Authors:  Prasit Mahawongkajit; Prakitpunthu Tomtitchong
Journal:  Mol Clin Oncol       Date:  2020-06-11

Review 2.  The frontline of esophageal cancer treatment: questions to be asked and answered.

Authors:  Cheng-Che Tu; Po-Kuei Hsu
Journal:  Ann Transl Med       Date:  2018-02

3.  Effectiveness evaluation of adjuvant concurrent chemoradiotherapy for patients with positron emission tomography-staged esophageal squamous cell carcinoma after complete resection: A population-based cohort study.

Authors:  Hsin-Yuan Fang; Yu-Sen Lin; Chien-Kuang Chen; Jian-Xun Chen; Ting-Yu Lu; Tzu-Min Huang; Te-Chun Hsieh; Yu-Cheng Kuo; Chen-Yuan Lin; Ming-Yu Lien; Chi-Ching Chen; Chia-Chin Li; Chun-Ru Chien
Journal:  Thorac Cancer       Date:  2022-06-03       Impact factor: 3.223

4.  A retrospective study of pattern of recurrence after radical surgery for thoracic esophageal carcinoma with or without postoperative radiotherapy.

Authors:  Yichun Wang; Li Zhang; Dongmei Ye; Wanli Xia; Jun Jiang; Xiumei Wang; Mingxia Zhang; Fan Wang
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

5.  Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Authors:  Andreas Fountoulakis; John Souglakos; Louiza Vini; Gerasimos N Douridas; Anna Koumarianou; Panteleimon Kountourakis; Christos Agalianos; Andreas Alexandrou; Christos Dervenis; Sofia Gourtsoyianni; Nikolaos Gouvas; Maria-Angeliki Kalogeridi; Georgia Levidou; Theodoros Liakakos; Joseph Sgouros; Spiros N Sgouros; Charikleia Triantopoulou; Evangelos Xynos
Journal:  Updates Surg       Date:  2019-12-02

6.  Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma.

Authors:  Hui-Shan Chen; Po-Kuei Hsu; Chia-Chuan Liu; Shiao-Chi Wu
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

7.  Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: Analysis of surveillance, epidemiology, and end results database.

Authors:  Jing Yu; Wen Ouyang; Yi Li; Jing Hu; Yu Xu; Yongchang Wei; Zhengkai Liao; Yu Liu; Junhong Zhang; Conghua Xie
Journal:  Cancer Med       Date:  2018-12-18       Impact factor: 4.452

8.  Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer.

Authors:  Joerg Lindenmann; Melanie Fediuk; Nicole Fink-Neuboeck; Christian Porubsky; Martin Pichler; Luka Brcic; Udo Anegg; Marija Balic; Nadia Dandachi; Alfred Maier; Maria Smolle; Josef Smolle; Freyja Maria Smolle-Juettner
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

9.  Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients.

Authors:  Jingjing Kang; Joe Y Chang; Xin Sun; Yu Men; Hongmei Zeng; Zhouguang Hui
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

10.  Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report.

Authors:  Kosuke Hirose; Hiroshi Saeki; Yuichiro Nakashima; Tomohiro Kamori; Yoshiaki Fujimoto; Tetsuro Kawazoe; Hiroya Matsuoka; Yasuhiro Haruta; Shun Sasaki; Tomoko Jogo; Qingjiang Hu; Yasuo Tsuda; Koji Ando; Eiji Oki; Ryuzo Hiratsuka; Yoshinao Oda; Masaki Mori
Journal:  Surg Case Rep       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.